Lineage Therap AI Stock Analysis
Want to see LCTX full AI Analyst Report?
Lineage Therap (LCTX) AI Stock Analysis
Lineage Therap
(NYSE MKT:LCTX)
The score is held down primarily by weak financial performance (ongoing operating losses and cash burn, plus a recent TTM revenue decline) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook—pipeline expansion via the NeuroAirmid/HUNT1 acquisition, external trial funding, and runway guidance into Q2 2028—though valuation support is limited given the very high P/E and no dividend yield.
Lineage Therap (LCTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $201.12M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.53M
- Price to Earnings (P/E)
- 128.3
- Beta (1Y)
- 1.01
- Revenue Growth
- 0.18%
- EPS Growth
- ―
- Country
- US
- Employees
- 75
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Lineage Therap Business Overview & Revenue Model
Company Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...
How the Company Makes Money
Lineage primarily makes money through (1) collaboration and license-related revenue and (2) raising capital, rather than through product sales, because it is a clinical-stage company without broadly commercialized products. Collaboration/licensing ec...
Lineage Therap Earnings Call Summary
The call was strongly optimistic, centered on the transformational NeuroAirmid acquisition, the addition of HUNT1 as a third clinical-stage asset, positive preclinical findings, early safety observations, external trial funding, manufacturing capabilities, and an extended cash runway. The company also reported progress across ILT1, COR1, ReSonance, OpRegen, and OPC1. Offsetting factors included lower revenue, higher operating expenses, a wider operating loss, uncertainty over partner-controlled OpRegen timing, and the early stage of HUNT1 clinical and manufacturing validation. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management updated run rate guidance into Q2 2028, which is 1 quarter earlier than prior guidance, and said $45.2 million in cash, cash equivalents and marketable securities as of September 30, 2026, is expected to fund planned operations into the second quarter of 2028; REGEN4HD clinical costs are estimated to run less than $2 million per year within a historic budget run rate of approximately $30 million per year, with up to approximately $2.6 million in cash, $2.4 million worth of Lineage common shares and a $356,000 cash payment due on the first anniversary of closing; Lineage remains eligible for approximately $32 million from warrants with a strike price of $0.91 and up to $615 million in development and commercial milestone payments; COR1 initial preclinical data are expected internally by year-end and publicly in the first quarter of 2027, ReSonance’s scientific advice meeting is scheduled for December, the third OPC1 DOSED patient is scheduled for surgery before year-end and a fourth patient is expected to be dosed in Q1, and the 21-patient Phase Ib/IIa REGEN4HD trial is currently enrolling.
Lineage Therap Financial Statement Overview
Summary
Overall financial quality is constrained by persistent operating losses and ongoing cash burn (negative operating and free cash flow), even as the balance sheet is conservatively levered with low debt. High gross margins are a positive, but recent TTM revenue decline and the mismatch between TTM net income and negative cash flow point to earnings quality risk.
Income Statement
34NegativeBalance Sheet
72PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.84M | 14.56M | 9.50M | 8.95M | 14.70M | 3.90M |
| Gross Profit | 10.39M | 13.71M | 9.16M | 8.27M | 13.97M | 2.47M |
| EBITDA | -2.16M | -67.95M | -17.97M | -22.59M | -25.09M | -42.40M |
| Net Income | 1.75M | -63.53M | -18.61M | -21.49M | -26.27M | -43.02M |
Balance Sheet | ||||||
| Total Assets | 100.11M | 112.58M | 113.22M | 101.02M | 123.66M | 174.54M |
| Cash, Cash Equivalents and Short-Term Investments | 45.18M | 55.78M | 47.80M | 35.49M | 57.88M | 58.36M |
| Total Debt | 2.03M | 2.42M | 2.51M | 2.95M | 3.90M | 2.80M |
| Total Liabilities | 34.17M | 69.24M | 36.21M | 39.00M | 51.73M | 83.65M |
| Stockholders Equity | 67.06M | 44.55M | 78.38M | 63.42M | 73.34M | 92.22M |
Cash Flow | ||||||
| Free Cash Flow | -26.00M | -19.44M | -23.66M | -29.24M | 646.00K | -23.91M |
| Operating Cash Flow | -25.82M | -18.92M | -23.09M | -28.57M | 1.06M | -23.56M |
| Investing Cash Flow | -18.85M | -13.46M | -2.31M | 46.45M | -46.16M | 9.74M |
| Financing Cash Flow | 30.38M | 26.95M | 35.86M | 6.42M | 1.63M | 36.93M |
Lineage Therap Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LCTX, the sentiment is Negative. The current price of 0.80 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 0.99, and below the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.03 is Neutral, neither overbought nor oversold. The STOCH value of 10.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LCTX.
Lineage Therap Risk Analysis
Lineage Therap disclosed 79 risk factors in its most recent earnings report. Lineage Therap reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksLineage Therap Peers Comparison
Overall Rating
AMRN50Neutral
LCTX48Neutral
DBVT47Neutral
TVRD47Neutral
FDMT45Neutral
AURA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | $238.43M | -10.77 | -4.26% | ― | -22.43% | 78.01% | |
| 48Neutral | $201.12M | 128.29 | 3.10% | ― | 0.18% | ― | |
| 47Neutral | $646.80M | -3.43 | -121.83% | ― | ― | 42.37% | |
| 47Neutral | $14.70M | -0.42 | -179.86% | ― | -100.00% | 67.96% | |
| 45Neutral | $623.71M | -4.08 | -47.06% | ― | 79952.50% | 29.07% | |
| 41Neutral | $751.42M | -4.31 | -64.69% | ― | ― | 13.33% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | 0.80 | -0.91 | -53.51% | |
| AMRN | Amarin Corporation Plc | 11.31 | -5.67 | -33.39% | |
| TVRD | Tvardi Therapeutics Inc. | 1.10 | -2.83 | -72.01% | |
| DBVT | DBV Technologies S.A. - American Depositary Shares | 10.27 | -4.03 | -28.18% | |
| FDMT | 4D Molecular Therapeutics, Inc. | 11.29 | 0.49 | 4.54% | |
| AURA | Aura Biosciences Inc | 7.22 | 1.82 | 33.70% |
Lineage Therap Corporate Events
Lineage Therapeutics Acquires NeuroAirmid, Expanding Cell Therapy Pipeline
PositiveOn November 12, 2026, Lineage acquired all outstanding shares of NeuroAirmid Therapeutics, making it a wholly owned subsidiary and adding HUNT1, a pluripotent stem cell-derived neural cell therapy for Huntington’s disease. HUNT1 was being evaluated i...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
